Clinical Trials Logo

Primary Hypercholesterolemia clinical trials

View clinical trials related to Primary Hypercholesterolemia.

Filter by:

NCT ID: NCT00871351 Completed - Clinical trials for Primary Hypercholesterolemia

Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Start date: February 1, 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.

NCT ID: NCT00867165 Completed - Clinical trials for Primary Hypercholesterolemia

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Start date: May 21, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children >=6 to <=10 years old with primary hypercholesterolemia. The study will also evaluate the effect of ezetimibe on total cholesterol (TC), apolipoprotein B (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides (TG). The safety of ezetimibe in this subject population will also be evaluated.

NCT ID: NCT00776321 Completed - Clinical trials for Primary Hypercholesterolemia

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

Start date: September 2006
Phase: Phase 2
Study type: Interventional

Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has in a clinical 2-weeks studies demonstrated pronounced reduction of independent risk factors for the development of atherosclerotic cardiovascular diseases. The purpose of the study is to assess the efficacy and safety of KB2115 as monotherapy following 12 weeks of exposure compared to placebo. The aim of the study is to assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115.

NCT ID: NCT00746811 Completed - Clinical trials for Primary Hypercholesterolemia

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

Start date: January 2010
Phase: Phase 4
Study type: Interventional

The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo, on LDL-C and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.

NCT ID: NCT00724477 Completed - Clinical trials for Primary Hypercholesterolemia

Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)

Start date: October 2007
Phase:
Study type: Observational

The main objective of this study is to determine the percentage of patients who met the low-density lipoprotein cholesterol (LDL-C) objective with INEGY, that were not under statin monotherapy treatment.

NCT ID: NCT00704535 Completed - Clinical trials for Primary Hypercholesterolemia

Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

Start date: March 2006
Phase:
Study type: Observational

The purpose of this study is to evaluate the overall safety, tolerability, and efficacy of Ezetimibe when used alone or in combination with a statin in patients with hypercholesterolemia

NCT ID: NCT00479882 Completed - Clinical trials for Primary Hypercholesterolemia

MK-0524B Lipid Study (MK-0524B-063)

Start date: June 15, 2007
Phase: Phase 3
Study type: Interventional

This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on lipid values.

NCT ID: NCT00479388 Completed - Clinical trials for Primary Hypercholesterolemia

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.

NCT ID: NCT00269217 Completed - Clinical trials for Primary Hypercholesterolemia

Lipid Efficacy Study (0524B-022)(COMPLETED)

Start date: January 2006
Phase: Phase 3
Study type: Interventional

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

NCT ID: NCT00249249 Completed - Dyslipidemia Clinical Trials

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.